Parsippany, New Jersey-based Onkos Surgical, Inc. has entered into an agreement with Kalamazoo, Michigan-based Stryker Corporation to purchase its Juvenile Tumor System (JTS).
According to the company, the JTS is designed for “pediatric patients affected by bone cancers, severe arthropathy, severe trauma, revisions, oncology, and malignant diseases.” The system facilitates limb stabilization and growth.
OTW spoke with Onkos Co-Founder and CEO Patrick Treacy about the acquisition. “Onkos Surgical is focused on delivering innovative solutions for musculoskeletal oncology and other complex orthopaedic conditions. We are delighted to announce the acquisition of the JTS technology as it has a successful, global clinical heritage and serves an important group of patients dealing with the challenges associated with bone cancer.”
Treacy continued, “We are committed to the stewardship of this heritage and our innovation initiatives that may help improve outcomes for musculoskeletal oncology surgeons and the patients they serve.”
During the conversation, Treacy also talked about what originally drew Onkos to JTS. “With our innovation and commercial focus, we have a keen understanding of the specialized needs of our customers. Since our founding in 2015, we have developed a portfolio of innovation to help address some of those clinical challenges and we are always looking to build upon our portfolio of solutions.”
Treacy added, “The JTS has a long-standing track record of clinical performance in an area that we did not offer a solution. The acquisition was a natural fit as the JTS is a device that allows for non-invasive lengthening of the implant eliminating the need for multiple lengthening surgeries, anesthesia or sedation and therefore helps reduce the risk of complications and cost associated with limb reconstruction surgery.”
Treacy also spoke with OTW about how the addition of JTS complements the current Onkos offerings. Treacy told OTW, “JTS is a wonderful addition and complement to our portfolio of reconstructive products used for bone loss. The JTS products are largely used by our existing surgeon and hospital customer base.”
Treacy continued, “Over the last five years, we have released multiple new implant designs focused on addressing prevalent clinical challenges, as well as an advanced case planning platform geared toward reducing the complexity of these cases. Adding the JTS Extendible Prosthesis to our portfolio allows us to help surgeons treat the needs of the pediatric patient; preserving their limb and providing a mechanism to address growth.”
